FZ-A038

FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) [1].

Product Specifications

UNSPSC

12352203

Target

ADC Antibody

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fz-a038.html

Purity

99.22

Smiles

[FZ-A038]

Molecular Weight

(145 kDa)

References & Citations

[1]Guo Q, et al., FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Oct 1;23 (10) :1367-1377. |[2]Guo Q, et al., FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Oct 1;23 (10) :1367-1377.